Announced
Completed
Financials
Tags
manufacture
pharmaceuticals
innovative specialty services
development of speciality medicine
Biotechnology
Ireland
pharmaceuticals manufacturing
Pharmaceuticals
United Kingdom
Public
Scheme
Friendly
Single Bidder
Completed
Synopsis
Takeda Pharmaceuticals and Shire completed a deal pursuant to which Takeda acquired the entire issued and to be issued ordinary share capital of Shire. Under the terms of the acquisition, each Shire shareholder received $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs. "Over the last 30 years, Shire has become the global leader in treating rare diseases, delivering innovative products that transform patients’ lives. With this combination, Shire helps create an even stronger biopharmaceutical company, with a robust R&D pipeline and expanded global footprint. We are proud of what Shire has become and are grateful to all Shire employees for their contributions. We firmly believe that this combination recognizes the strong growth potential of our leading products and innovative pipeline and is in the best interests of our shareholders, our patients and the communities we serve," Susan Kilsby, Shire chairman.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.